Your browser doesn't support javascript.
loading
Modeling interaction of Glioma cells and CAR T-cells considering multiple CAR T-cells bindings.
Li, Runpeng; Sahoo, Prativa; Wang, Dongrui; Wang, Qixuan; Brown, Christine E; Rockne, Russell C; Cho, Heyrim.
Afiliação
  • Li R; Department of Mathematics, University of California Riverside, 900 University Ave., Riverside, 92521, CA, USA.
  • Sahoo P; Division of Mathematical Oncology, Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope National Medical Center, 1500 E Duarte Rd., Duarte, 91010, CA, USA.
  • Wang D; Zhejiang University Medical Center, 866 Yuhangtang Rd, Hangzhou, 310058, PR China.
  • Wang Q; Department of Mathematics, University of California Riverside, 900 University Ave., Riverside, 92521, CA, USA.
  • Brown CE; Interdisciplinary Center for Quantitative Modeling in Biology, University of California Riverside, 900 University Ave., Riverside, 92521, CA, USA.
  • Rockne RC; Department of Hematology & Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope National Medical Center, 1500 E Duarte Rd., Duarte, 91010, CA, USA.
  • Cho H; Division of Mathematical Oncology, Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope National Medical Center, 1500 E Duarte Rd., Duarte, 91010, CA, USA.
Article em En | MEDLINE | ID: mdl-36875891
ABSTRACT
Chimeric antigen receptor (CAR) T-cell based immunotherapy has shown its potential in treating blood cancers, and its application to solid tumors is currently being extensively investigated. For glioma brain tumors, various CAR T-cell targets include IL13Rα2, EGFRvIII, HER2, EphA2, GD2, B7-H3, and chlorotoxin. In this work, we are interested in developing a mathematical model of IL13Rα2 targeting CAR T-cells for treating glioma. We focus on extending the work of Kuznetsov et al. (1994) by considering binding of multiple CAR T-cells to a single glioma cell, and the dynamics of these multi-cellular conjugates. Our model more accurately describes experimentally observed CAR T-cell killing assay data than the models which do not consider multi-cellular conjugates. Moreover, we derive conditions in the CAR T-cell expansion rate that determines treatment success or failure. Finally, we show that our model captures distinct CAR T-cell killing dynamics from low to high antigen receptor densities in patient-derived brain tumor cells.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article